Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study

J Neuroimmunol. 2019 Jan 15:326:19-27. doi: 10.1016/j.jneuroim.2018.11.002. Epub 2018 Nov 7.

Abstract

Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.

Keywords: Anti-drug antibodies; Bridging ELISA; Interferon-beta; Luciferase-based bioassay; Multiple sclerosis; Neutralizing antibodies.

Publication types

  • Comparative Study
  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing / blood*
  • Biological Assay
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Immunologic Factors / immunology
  • Immunologic Factors / therapeutic use
  • Interferon-beta / immunology
  • Interferon-beta / therapeutic use
  • Male
  • Multiple Sclerosis / blood*
  • Multiple Sclerosis / drug therapy
  • Neutralization Tests / methods*

Substances

  • Antibodies, Neutralizing
  • Immunologic Factors
  • Interferon-beta